Metformin Teva Uk (Metformin Hydrochloride)

Metformin works by inhibiting hepatic gluconeogenesis, which reduces the liver’s production of glucose. It also enhances peripheral insulin sensitivity, allowing muscle and fat cells to take up glucose more efficiently, and modestly reduces intestinal glucose absorption.

The appropriate dose of Metformin Teva Uk is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Dosage adjustments are made individually and should follow the prescriber’s instructions.

Metformin may be used during pregnancy or lactation only when clearly needed and after a risk‑benefit assessment by the prescriber. It crosses the placenta and is excreted in breast milk, so clinicians should discuss potential advantages and risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Metformin Teva Uk. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with sulfonylureas or insulin, Metformin does not cause weight gain and has a low risk of hypoglycaemia when used alone. It is often preferred as first‑line therapy for type 2 diabetes because of its efficacy, safety profile, and cardiovascular benefits observed in large clinical studies.

Metformin Teva Uk tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Metformin Teva Uk is taken orally, usually with meals to minimise gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or chew the tablets unless instructed otherwise.

The most serious risk is lactic acidosis, a rare but potentially fatal condition characterized by rapid breathing, muscle pain and abdominal discomfort. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant vitamin B12 deficiency with long‑term use.

Metformin is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, known hypersensitivity to metformin, and those receiving iodinated contrast studies without adequate renal monitoring. Clinicians should assess each patient’s medical history before initiating therapy.